Literature DB >> 22288585

The autoreactivity of B cells in hereditary angioedema due to C1 inhibitor deficiency.

A Kessel1, R Peri, R Perricone, M D Guarino, Z Vadasz, R Novak, T Haj, S Kivity, E Toubi.   

Abstract

Patients with hereditary angioedema (HAE) tend to produce autoantibodies and have a propensity to develop immunoregulatory disorders. We characterize the profile of autoantibodies in a group of HAE patients and investigate their memory B cells' phenotype and activation status. We studied the activity status phenotype, Toll-like receptor (TLR)-9 expression and total phosphotyrosine in B cells isolated from HAE patients. Additionally, the following autoantibodies were assessed in the serum of 61 HAE patients: anti-nuclear, rheumatoid factor, anti-cardiolipin, anti-tissue transglutaminase, anti-endomysial, anti-Saccharomyces cerevisiae, anti-thyroid and anti-neutrophil cytoplasmic antibodies. In 47·5% of HAE patients we detected at least one of the tested autoantibodies. Expression of CD69, CD5 and CD21 was found to be significantly higher on memory B cells from HAE patients compared to healthy controls (4·59 ± 4·41 versus 2·06 ± 1·81, P = 0·04, 8·22 ± 7·17 versus 3·65 ± 3·78, P = 0·05, 2·43 ± 0·54 versus 1·92 ± 0·41, P = 0·01, respectively). Total phosphotyrosine in B cells from HAE patients was significantly higher compared to healthy controls (4·8 ± 1·1 versus 2·7 ± 1·3, P = 0·0003). Memory B cells isolated from the HAE group contained higher amounts of TLR-9 compared to healthy controls (8·17 ± 4·1 versus 4·56 ± 1·6, P = 0·0027). Furthermore, the expression of TLR-9 in memory B cells from HAE patients with autoantibodies was significantly higher than the control group (10 ± 4·7 versus 4·56 ± 1·6, P = 0·0002) and from that in HAE patients without autoantibodies (10 ± 4·7 versus 5·8 ± 0·9, P = 0·036). HAE patients have enhanced production of autoantibodies due most probably to the increased activation of B cells, which was found to be in association with a high expression of TLR-9.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22288585      PMCID: PMC3374274          DOI: 10.1111/j.1365-2249.2011.04527.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Mechanism and function of a newly identified CpG DNA motif in human primary B cells.

Authors:  G Hartmann; A M Krieg
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

Review 2.  Systemic lupus erythematosus, complement deficiency, and apoptosis.

Authors:  M C Pickering; M Botto; P R Taylor; P J Lachmann; M J Walport
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

3.  Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency.

Authors:  Henriette Farkas; Dorottya Csuka; Judit Gács; Ibolya Czaller; Zsuzsanna Zotter; George Füst; Lilian Varga; Péter Gergely
Journal:  Clin Immunol       Date:  2011-05-19       Impact factor: 3.969

4.  Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.

Authors:  Eun D Han; Ryan C MacFarlane; Aideen N Mulligan; Jennifer Scafidi; Alvin E Davis
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 5.  The role of CD5-expressing B cells in health and disease (review).

Authors:  J O Pers; C Jamin; F Predine-Hug; P Lydyard; P Youinou
Journal:  Int J Mol Med       Date:  1999-03       Impact factor: 4.101

6.  Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema.

Authors:  Sujoy Khan; Michael D Tarzi; Philip C Doré; W A C Sewell; Hilary J Longhurst
Journal:  Clin Immunol       Date:  2006-11-13       Impact factor: 3.969

7.  Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases.

Authors:  Guadalupe G Marin; Mario H Cardiel; Horacio Cornejo; Martha E Viveros
Journal:  J Clin Rheumatol       Date:  2009-10       Impact factor: 3.517

8.  Antinuclear antibodies by indirect immunofluorescence : optimum screening dilution for diagnosis of systemic lupus erythematosus.

Authors:  P Ghosh; S Dwivedi; Sita Naik; Vikas Agarwal; Anupam Verma; Amita Aggarwal; Ramnath Misra
Journal:  Indian J Med Res       Date:  2007-07       Impact factor: 2.375

9.  An association between C1 esterase inhibitor deficiency and lupus erythematosus: report of two cases and review of the literature.

Authors:  M C Massa; S M Connolly
Journal:  J Am Acad Dermatol       Date:  1982-08       Impact factor: 11.527

10.  A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo.

Authors:  P R Taylor; A Carugati; V A Fadok; H T Cook; M Andrews; M C Carroll; J S Savill; P M Henson; M Botto; M J Walport
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

View more
  5 in total

1.  Multiscale modelling of relationships between protein classes and drug behavior across all diseases using the CANDO platform.

Authors:  Geetika Sethi; Gaurav Chopra; Ram Samudrala
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

2.  Disease-modifying factors in hereditary angioedema: an RNA expression-based screening.

Authors:  Alberto López-Lera; Fátima Sánchez Cabo; Sofía Garrido; Ana Dopazo; Margarita López-Trascasa
Journal:  Orphanet J Rare Dis       Date:  2013-05-20       Impact factor: 4.123

3.  Systemic lupus erythematosus with various clinical manifestations in a patient with hereditary angioedema: a case report.

Authors:  Yusuke Ushio; Risa Wakiya; Tomohiro Kameda; Shusaku Nakashima; Hiromi Shimada; Mai Mahmoud Fahmy Mansour; Mikiya Kato; Taichi Miyagi; Koichi Sugihara; Rina Mino; Mao Mizusaki; Emi Ibuki; Norimitsu Kadowaki; Hiroaki Dobashi
Journal:  Allergy Asthma Clin Immunol       Date:  2022-09-18       Impact factor: 3.373

Review 4.  Roles of Immune Cells in Hereditary Angioedema.

Authors:  Anne Lise Ferrara; Leonardo Cristinziano; Angelica Petraroli; Maria Bova; Maria Celeste Gigliotti; Simone Marcella; Luca Modestino; Gilda Varricchi; Mariantonia Braile; Maria Rosaria Galdiero; Giuseppe Spadaro; Stefania Loffredo
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-29       Impact factor: 8.667

5.  In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency.

Authors:  A L Manson; A Price; J Dempster; P Clinton-Tarestad; C Greening; R Enti; S Hill; S Grigoriadou; M S Buckland; H J Longhurst
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.